Patient characteristics. Two comparisons were made for the purposes of this inves- tigation: (1) patients with bacteriuria vs nonbacteriuria control subjects (Table 1), and (2) UTI vs ASB subjects (Table 2). All 296 study subjects were white. ■ Patients with bacteriuria vs control subjects —When com- pared with individuals from the nonbacteriuria control group ( Table 1), patients with bacteriuria (either UTI or ASB) were more often: ▫ female (84% vs 75%; OR, 1.84; 95% CI, 1.03-3.26) ▫ nursing home residents (OR, 1.74; 95% CI, 1.08-2.80) ▫ had a history of hypertension (OR, 1.81; 95% CI, 1.14-2.87) ▫ received bladder catheterization in the ED or on admission (OR, 1.72; 95% CI, 1.08-2.74) JAOA • Vol 109 • No 4 • April 2009 • 221 ORIGINAL CONTRIBUTION Table 1 Bacteriuria in Hospitalized Older Adults: Characteristics and Acute Discharge Diagnosis for Subjects With Bacteriuria vs Nonbacteriuria Control Subjects (N=296)* Characteristics Bacteriuria Group (n=154) Nonbacteriuria Control Group (n=142) Crude Odds Ratio (95% Confidence Interval) ■ Mean (SD) Age, y 83 (8) 82 (8) ... ■ Female 130 (84) 106 (75) 1.84 (1.03-3.26)† ■ Nursing Home Resident 68 (44) 47 (33) 1.74 (1.08-2.80)† ■ Medical History ▫ Cognitive impairment 47 (31) 38 (27) 1.20 (0.73-1.99) ▫ Cardiovascular health – Hypertension 93 (60) 65 (46) 1.81 (1.14-2.87)† – Stroke 30 (19) 34 (24) 0.77 (0.44-1.34) ▫ Pulmonary disease – Chronic obstructive pulmonary disease 33 (21) 36 (25) 0.80 (0.47-1.38) – Pneumonia 16 (10) 19 (13) 0.75 (0.37-1.52) ▫ Diabetes mellitus 45 (29) 34 (24) 1.31 (0.78-2.20) ▫ Falls 16 (10) 9 (6) 1.71 (0.73-4.01) ■ Hospital Care‡ ▫ Bladder catheter 78 (51) 53 (37) 1.72 (1.08-2.74)† ▫ Antibiotic treatment 92 (60) 67 (47) 1.66 (1.05-2.63) † – Levofloxacin treament 53 (58) 26 (39) 2.09 (1.10-3.96)† Acute Discharge Diagnosis ■ Ischuria§ 5 (4) 11 (8) 0.44 (0.15-1.31) ■ Delirium 46 (30) 11 (8) 5.07 (2.51-10.27)† ■ Cardiovascular Health ▫ Atrial fibrillation 19 (12) 19 (13) 0.91 (0.46-1.80) ▫ Congestive heart failure 31 (20) 18 (13) 1.74 (0.92-3.27) ■ Pulmonary Disease 42 (27) 59 (42) 0.53 (0.32-0.86)† ▫ Pneumonia 23 (15) 32 (23) 0.60 (0.33-1.09) ■ Diabetes Mellitus With Hyperglycemia 32 (21) 27 (19) 1.12 (0.63-1.98) ■ Falls 26 (17) 20 (14) 1.24 (0.66-2.33) ▫ Fracture 8 (5) 12 (8) 0.59 (0.23-1.50) ▫ No fracture 18 (12) 8 (6) 2.22 (0.93-5.27) ■ Blood Test Results ▫ Serum urea nitrogen/ creatinine ratio, “20:1 79 (51) 68 (48) 1.15 (0.73-1.81) ▫ Electrolyte panel (imbalance) 51 (33) 58 (41) 0.72 (0.45-1.15) ▫ Serum albu...
Patient characteristics. A total of 299 patients (79%) participating in the GIPS-III trial underwent 2D TTE assessment, image quality was insufficient to determine LV mass in 9 subjects and to determine LV volumes in 38 subjects. CMR was performed in 275 patients (73%), image quality was insufficient to determine LV mass in 8 subjects and to determine LV volumes in 4 subjects. CMR and 2D TTE measurements were available in 259 patients (61%), of which LV mass measurements in both imaging modalities were available in 255 patients and LV volume measurements in 236 patients. In-hospital clinical, angiographic and biochemical characteristics, as well as medication at discharge, are presented in Table 1. Median infarct size was 7.2% (2.6, 13.7) of LV mass.
Patient characteristics. Data are expressed as the median (range). The mild asthmatics prior to challenge (n=11) are included in the total of 21 mild asthmatics.
Patient characteristics. Table 1 shows that the 190 patients who completed the questionnaire had a mean age of 49 years (SD=16), 94 (49%) were female and 52 (27%) were living alone. The majority of patients followed either a “higher education” (41%) or “middle education” (41%) and 19% received “lower education”. Most patients were diagnosed with “acquired brain injury” (42%), followed by “neuromuscular disease” (13%) and “orthopaedics” (6%). The majority of the patients (73%) had outpatient rehabilitation treatment, 20 patients (10%) had inpatient rehabilitation, 26 patients (14%) had had both and two patients (1%) received a short rehabilitation program for heart rehabilitation. The eligible patients had a mean age of 44 years (SD=19) and 341 (49%) were female. No significant differences were found for age and gender between the group of eligible patients and group of responded patients.
Patient characteristics. Patient characteristics are given in Table 1. The age of the subjects varied from 13 to 77 years, with the average of 43 years by the time of taking the CT scans (Table 1). 23 (40%) of the patients were men. 29 (51%) of the whole group had allergic rhinitis, 13 (23%) had diagnosed asthma and 13 (23%) had nasal polyps (Table 1). 35 out of 57 patients ended up having sinonasal surgery during the following 12 months after they had undergone sinus CT scans (Table 1). The regularly used medications excluding those for CRS or related diseases were for heart and vascular diseases (10 patients), hypothyreosis (5 patients), migraine (3 patients), hyper-cholesterolemia (2 patients), gastroesophageal reflux disease (2 patients), cystitis (1 patient), irritable bowel syndrome (1 patient), melanoma (1 patient), otosclerosis (1 patient), prostate hypertrophy (1 patient) and rheumatoid arthritis (1 patient). The median (min-max) duration of CRS symptoms was 8.3 (0-54 years) prior to taking the CT scan (Table 1). The median (min-max) number of antibiotic courses for acute rhinosinusitis during the past two years was 4.8 (0-15) (Table 1). The median VAS scores of sinonasal symptoms were between 3.5-5.8 (Table 1). 46 (81%) of the patients had current use of intranasal corticosteroids. None of the patients reported as having used peroral corticosteroids during the past 12 months (Table 1). 12 (21%) of the patients had undergone a previous sinus operation such as inferior or middle meatal antrostomy and/or ethmoidectomy (Table 1). The median (Q1-Q3) total Lund-MacKay score was 3 (1-5) on both sides (Table 2). Inter-observer agreement
Patient characteristics. Characteristics Number (percentage) Gender Male Female Clinical diagnosis Nevus PAM Melanoma 33 (49) 35 (51) 31 (46) 28 (41) 9 (13) Location Caruncle 10 (15) Fornix 3 (4) Bulbus 55 (81) (Limbal * 36 (65)) * Number of bulbar lesions that were located at the limbus. PAM = Primary acquired melanosis membrane, the device is placed in a slightly larger plastic tube. The eye is anaesthetized with 1-2 drops of 0.4% oxybuprocaine (mono free, Théa Pharma, Ukkel, Belgium), and the eyelids are opened for a few seconds to dry the conjunctiva to improve the adherence of cells onto the Biopore membrane. The Biopore membrane is pressed gently onto the conjunctiva, after 3-5 seconds the Biopore is removed and immediately fixed and stained with RAL 555 (555-FIX-RAL, 000-Xxxxx-XXX, 000-Xxxx-XXX, Reactifs RAL Bordeaux technopols, Mar- tillac, France). The Biopore membrane is submerged in each of the three RAL 555 solutions (methanol, eosin, methylene blue) for approximately 10 seconds. After staining, the mem- brane is cut out with a 15-degree knife and fixed with mounting medium on a glass slide for microscopic evaluation. After Biopore sampling, the same lesions are swabbed with a cotton-wool tip for exfoliative cytology. The cells on the cotton-wool tip are than transferred to several glass slides, pro- cedure is repeated three times to acquire more cells for analysis. The glass slides of the ex- foliative cytology are processed under standard protocol used in our hospital. Cytological interpretation Exfoliative cytology and Biopore membranes were all interpreted by two cyto-pathologists (MVC and SV). When there was disagreement between the two observers a third independ- ent observed made the final decision. All Biopore samples were numbered, and bias through prior knowledge of the exfoliative cytology was therefore excluded. Both exfoliative smears as well as Biopore samples were graded by a standard grading system used in our hospital. In brief, the samples were screened for: nuclear size, nuclear to cytoplasmatic ratio, irregular nucleus, irregular nuclear chromatin pattern, and prominent nucleoli, and subsequently graded into four different stages, 0: insufficient material for diagnosis, 1: normal epithelial conjunctival cells with or without melanin pigment, reactive conjunctival cells as seen in in- flammation, 2: melanocytes with mild atypia, 3: melanocytes with moderate atypia, 4: melanocytes with severe atypia.11 The amount of cells collected (low, moderate, hig...
Patient characteristics. Patient demographics including age, gender, screening height and weight, and other demographic characteristics will be summarized using descriptive statistics. Baseline disease characteristics will be summarized by presenting frequency counts and percentages for disease characteristics as appropriate.
Patient characteristics. Patient Characteristics (n=863) Male (%) 646 (74.9) Age (years) 61 ± 13 BMI (kg/m2) 28.4 (24.9-41.1) BMI ≥30 kg/m2 (%) 374 (43.3) Region of residency (%) 1 265 (30.7) 2 253 (29.3) 3 185 (21.4) 4 160 (18.5) Risk factors for coronary diseases (%) Smoking 462 (53.5) Hypertension 307 (35.6) Hyperlipidemia 167 (19.4) Family History 358 (41.5) Diabetes Mellitus 108 (12.5) Prior Myocardial Infarction 90 (10.4) Median time intervals in minutes (IQR) Onset Symptoms - Arrival at Cath-Lab 150 (101-280) Door - Arrival at Cath-Lab 23 (13-42) Onset Symptoms – Alert of Emergency Services 61 (25-158) Alert of Emergency Services – Arrival at Hospital 48 (40-60) Hospitalization Days hospitalized (median [IQR]) 2 (2-3)
Patient characteristics. Between 2010 and 2012, a total of 12,529 patients received at least one platelet transfusion in Denmark. Of these, 826 patients were excluded based on age at time of transfusion and 1,927 patients were excluded as they only received a transfusion in a hospital that accounted for fewer than 1000 platelet transfusions in the study period. The final cohort consisted of 9,776 patients, more men than women (62.3% versus 37.7%), with an average age of 64.1 years (table 1). During the study period, these patients received 66,101 platelet transfusions, of which 22,240 units (33.6%) were stored for six or seven days. This relatively large proportion of old platelet concentrates is a consequence of the first-in-first-out policy. Forty-nine percent of all platelet concentrates were transfused to patients with a hematological malignancy, 15.6% to patients with trauma or xxxxx, and 8.6% to patients who underwent cardiothoracic surgery. The distribution of diagnoses was similar among the storage time categories. Information about blood group of the product was missing for 11,156 products, but this was equally distributed among the storage time categories. The proportion of rhesus D negative products increased with increasing storage time (Table 2). Table 1. Characteristics of study population Number of patients (%) Patients, n 9,776 Male, n (%) 6,088 (62.3) Age, n (%) 18-49 years 1,533 (15.7) 50-74 years 6,011 (61.5) ≥75 year 2,232 (22.8) Mean (SD) age in years 64.1 (14.6) Median (IQR) number of transfused platelet concentrates 2 (1-6) Median (IQR) number of transfused red blood cell concentrates 12 (5-24) Median (IQR) number of transfused plasma products 2 (0-8) Table 2. Characteristics of transfused platelet concentrates Storage time Storage time Total 1-5 days 6 -7 days Number of platelet concentrates (%)* 34,722 (52.5) 22,240 (33.6) 66,101 (100) Male, n(%)† 21,628 (62.3) 14,151 (63.6) 41692 (63.1) Mean (SD) age in years† 60.3 (14.9) 60.0 (15.1) 60.2 (14.9) Median (IQR) number of prior 32 (9-79) 33 (9-83) 34 (10-84) transfusions all products Main indication Hematology 17,029 (49.0) 10,681 (48.0) 32,547 (49.2) Cardiothoracic surgery 3,017 (8.7) 1,914 (8.6) 5,657 (8.6) Trauma and xxxxx 5,407 (15.6) 3,429 (15.4) 10,319 (15.6) Bleeding 1,177 (3.4) 675 (3.0) 2,106 (3.2) Unknown 8,092 (23.3) 5,541 (25.0) 15,472 (23.4) Donor ABO blood group, n (%) A 13,958 (40.2) 8,019 (36.1) 22,377 (33.9) B 1,551 (4.5) 510 (2.3) 2,084 (3.2) AB 9 (0.03) 1 (0.0) 15 (0.0) O 16,736 (48.2) 12,2...
Patient characteristics. Forty-seven patients (53.2% female, median age 62 years, range 22-74 years) and 47 healthy controls (76.6% female, median age 54 years, range 24-66 years) were vaccinated with the seasonal influenza vaccine from October to December 2016. Healthy controls were significantly younger (p=0.001) and were more frequently female (p=0.02) than the MG group. In the MG group, 23 patients randomly received a placebo injection followed by flu vaccination 4 weeks later. Baseline characteristics did not differ between the two MG patients groups that either received first the flu vaccination or the placebo vaccination. The MG group consisted of 29 patients with (IM+) and 18 without (IM-) immunosuppressive medication. The IM+ group was significantly older (p<0.01) than the IM- group and contained more female patients (p=0.04). Disease duration and whether a patient underwent a thymectomy in the past was not significantly different between IM- and IM+ groups (p=0.4 and p=0.16, respectively). Baseline characteristics are given in Table 1.
